Novel treatment may benefit patients with metabolic acidosis and kidney disease

(American Society of Nephrology) A new study demonstrated that TRC101, a hydrochloric acid binder for the treatment of metabolic acidosis associated with chronic kidney disease, provided a rapid and sustained average increase in serum bicarbonate.All adverse effects were mild or moderate.